Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: article date + pst + 0:00am  Related to the article below (Last Update: 7/8/2008)

trend tracking,
CNET News, CA -
By Josh Lowensohn ? March 6, 2008 11:22 AM PST 11 comments I've looked at a handful of price watching services, but this one has got to be the coolest. ...
meme trackers
CNET News, CA - Jul 2, 2008
By Josh Lowensohn ? January 18, 2008 11:11 AM PST Post a comment A lot of folks would like a memetracker for Google Reader (myself included), and if the big ...
Give It Up
Search Engine Roundtable - Jul 3, 2008
1PM PST on July 3rd. Danny says that there aren't women on this panel. He is going to kick out three guys next time. Stephan Spencer talks about conditional ...
e-commerce,
CNET News, CA - Jun 18, 2008
By Josh Lowensohn ? March 6, 2008 11:22 AM PST 10 comments I've looked at a handful of price watching services, but this one has got to be the coolest. ...
awesome back,
CNET News, CA - Jun 19, 2008
By Josh Lowensohn ? February 22, 2007 2:38 PM PST 3 comments YouBackItUp is a great way to share large files with friends. YouBackItUp has employed a really ...
site building
CNET News, CA - Jun 19, 2008
By Rafe Needleman ? February 29, 2008 5:20 PM PST 9 comments My first review of Google Sites was positive. I even chose to overlook some weird display ...
Read all 'Blog It' posts in Crave
CNET News, CA - Jun 12, 2008
10 am PST: Apple's special event today in Cupertino is about to get started, as a couple hundred people are gathered inside Apple's Town Hall auditorium at ...
COOL WEB 2.0 APPS FOR EVERYONE
CNET News, CA - Jun 17, 2008
... and in the future intends to spread its tour date and recommendation engine even further. By Caroline McCarthy ? March 5, 2008, 5:55 AM PST This post ...
Blizzard Teaser Image Speculation Heats Up Diablo 3 Announcement ...
Shacknews - Jun 24, 2008
Also added to the argument is the fact that Blizzard has never used a teaser reveal for a release date, supposedly ruling out a Lich King-related ...
A Few Firefox 3 Followups
Slashdot - Jun 18, 2008
Mary announced on the Spread Firefox Forum that downloads will commence at 10 AM PST." That means 1 pm East Coast time, and, in Justin Mason's view, ...
Source: Google News

… by tissue-specific alternative splicing Article published online before print. See web site for date … -
KM ELGADI, RA MEGUID, M QIAN, WW SOUBA, SF … - Physiological Genomics, 1999 - Am Physiological Soc
... endonuclease (Hind III, BamH I, EcoR I, Pst I, or ... Article published online before
print. See web site for date of publication (http://physiolgenomics.physiology ...

How Does Privatization Work? Evidence from the Russian Shops -
N Barberis, M Boycko, A Shleifer, N Tsukanova - Journal of Political Economy, 1996 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... Journal of
Economics 112:4, 965-1025 Online publication date: 1-Dec-1997. ... Top of Article.

… in the endothelium Article published online before print. See web site for date of publication (http … -
V EVANS, A HATZOPOULOS, WC AIRD, HB RAYBURN, RD … - Physiological Genomics, 2000 - Am Physiological Soc
... Kpn I, Xma I, BamH I, Xba I, Sal I, Pst I, Sfi I ... Article published online before
print ... See web site for date of publication (http://physiolgenomics.physiology.org ...

Can Imperfect Competition Explain the Difference between Primal and Dual Productivity Measures? … -
W Roeger - Journal of Political Economy, 1995 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... Review of
Income and Wealth 43:2, 227-238 Online publication date: 1-Jul ... Top of Article.

Dividends and Taxes: Some Empirical Evidence -
MH Miller, MS Scholes - The Journal of Political Economy, 1982 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a scheduled ...
Fiscal Studies 5:1, 1-17 Online publication date: 1-Mar-1984. ... Top of Article.

The Impact of New Product Introductions on the Market Value of Firms -
PK Chaney, TM Devinney, RS Winer - Journal of Business, 1991 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... Marketing
Letters 3:2, 137-145 Online publication date: 1-May-1992. ... Top of Article.

College Entry by Blacks since 1970: The Role of College Costs, Family Background, and the Returns to … -
TJ Kane - Journal of Political Economy, 1994 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... of Political
Economy 107:s6, S184-S224 Online publication date: 1-Dec-1999 ... Top of Article.

Endowments and the Allocation of Schooling in the Family and in the Marriage Market: The Twins … -
JR Behrman, MR Rosenzweig, P Taubman - Journal of Political Economy, 1994 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... of International
Development 8:3, 341-373 Online publication date: 1-Jun ... Top of Article.

Capital Controls, Political Risk, and Deviations from Interest-Rate Parity -
MP Dooley, P Isard - The Journal of Political Economy, 1980 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will ... Weltwirtschaftliches
Archiv 123:4, 606-617 Online publication date: 1-Jan-1988. ... Top of Article.

Saving Babies: The Efficacy and Cost of Recent Changes in the Medicaid Eligibility of Pregnant Women -
J Currie, J Gruber - Journal of Political Economy, 1996 - UChicago Press
Friday (March 7th 2008) starting at 3pm PST/6pm EST we will initiate a ... Review of
Public Health 20:1, 403-426 Online publication date: 1-Jun-1999 ... Top of Article.

Source: Google Scholar
 
 

Novel Drug Boosts Platelet Production, Reversing Chronic Immune Thrombocytopenic Purpura

Article Date: 19 Nov 2006 - 0:00am (PST)
Attacking a platelet-depleting autoimmune disease in a whole new way, an experimental drug is helping patients with immune thrombocytopenic purpura (ITP) once again produce healthy amounts of platelets -- with no major side effects.

That's the conclusion of a new, multicenter study led by Dr. James B. Bussel, professor of pediatrics at Weill Cornell Medical College, attending pediatrician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and director of the Hospital's Program for Platelet Disorders.

His team's findings appear in The New England Journal of Medicine.

The new drug, a novel protein called AMG 531, successfully boosted platelet production in patents with chronic ITP, a serious autoimmune disorder that affects more than 16,000 adult Americans, and perhaps as many children, each year.

Article continues below and (thank you)
 
In ITP, immune system antibodies mysteriously begin to attack and destroy blood platelet cells. In some cases, the disease goes into spontaneous remission, but for many patients it remains a chronic condition. Impaired clotting leaves many patients, especially the elderly, vulnerable to serious or fatal hemorrhage.

Up till now, ITP patients have typically turned to powerful drugs such as corticosteroids or intravenous immune globulin, which work by inhibiting platelet destruction. These drug therapies can have limited success, but they also have serious side effects. For some ITP patients splenectomy (surgical removal of the spleen) is another treatment option.

AMG 531 fights ITP in a totally different way.

"Experts have long realized that ITP not only destroys platelets, it also inhibits platelet production in the marrow," explains Dr. Bussel.

In fact, prior work in the 1990s had focused on a type of recombinant thrombopoietin, called PEG-MGDF, that researchers hoped would stimulate platelet production.
 
The drug did have success. "However, Dr. David Kuter at Massachusetts General Hospital showed that some patients -- and even healthy volunteers -- developed antibodies to the drug, and these antibodies cross-reacted with their own natural thrombopoietin. The result was chronic low platelet counts in people who, in many cases, had never had such problems before," Dr. Bussel says.

The trick, then, was to find a platelet-stimulating agent that avoided this dangerous immune-system response.

"Luckily, Amgen, the company that has funded this research, didn't throw in the towel," Dr. Bussel says.

The company, under the guidance of the study's senior author, Dr. Janet Nichol, eventually developed AMG 531 -- a novel protein with no structural similarity to human thrombopoietin. This dissimilarity and other features mean AMG 531 is largely ignored by the immune system.

The new, two-phase trial was led by Dr. Bussel and conducted at nine centers across the United States.

In the Phase 1 part of the study, doctors first gave six groups of four ITP patients (24 total) two subcutaneous injections of AMG 531 delivered at least two weeks apart. Depending on the group they were in, patients received anywhere from 0.2 to 10 micrograms of the drug per kilogram of body weight.

In the Phase 2 part of the trial, 21 patients were randomized to receive six weekly injections of either a harmless placebo, or AMG 531 at doses of 1, 3, or 6 micrograms per kilogram of body weight.

The Phase 1 results showed the drug to be safe, with no major adverse events attributed to AMG 531 during the treatment period. Four of a total of 41 patients did show some temporary post-treatment lowering of their platelet counts, but this later resolved.

The drug's efficacy impressed the researchers.

"We were very pleased," says Dr. Bussel. Hoping to boost platelet counts to between 50,000 to 450,000 per cubic millimeter, the researchers report that seven of 12 patients given higher doses of AMG 531 (3, 6 or 10 micrograms/kilogram) fell within that range after six weeks on the therapy.

"In fact, three of these patients saw their counts rise to over 450,000 per cubic millimeter," Dr. Bussel notes.

Platelet counts increased in treated patients in a dose-dependent fashion, with mean peak counts of 163,000, 309,000 and 746,000 per cubic millimeter for doses of 3, 6 and 10 micrograms/kilogram, respectively.

"This was a relatively small trial, so more study is needed. However, the results point to a new, effective and safe way of letting people receive an injection once a week that stimulates them to increase their platelets," Dr. Bussel says.

How does AMG 531 work? According to the researchers, the drug acts much like natural thrombopoietin, stimulating the production of platelets from their earliest stages of development within the marrow, straight through to their appearance in the bloodstream.

Based on the findings, Dr. Bussel is optimistic that ITP patients everywhere will soon have a potent new weapon against the disease.

"Further clinical trials in AMG 531 are well under way," he says, "and the next step, we hope, will be to license the compound. Then, maybe, we can begin to broaden its use to other illnesses, where boosting platelets might help the many other patients with low platelets fight disease."

Co-researchers include Dr. David J. Kuter of Massachusetts General Hospital, Boston; Dr. James N. George of the University of Oklahoma Medical Center, Oklahoma City; Drs. Robert MacMillan and Jorge Nieva, of Scripps Cancer Center, La Jolla, Calif; Dr. Louis M. Aledort of Mount Sinai Medical Center, New York City; Dr. George T. Conklin of the Diagnostic Clinic of Houston; Dr. Alan E. Lichtin, of the Cleveland Clinic Foundation; Dr. Roger M. Lyons of Hematology-Oncology Associates of South Texas, San Antonio; Dr. Jeffrey S. Wasser of DeQuattro Community Cancer Center, Manchester, Conn; Dr. Israel Wiznitzer of the Broward General Medical Center, Fort Lauderdale, Fla; and Reggie Kelly and Dr. Chien-Feng Chen, of Amgen, Thousand Oaks, Calif.

NewYork-Presbyterian Hospital
425 East 61st St., Fl. 7
New York, NY 10021
United States
http://www.nyp.org
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page